Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region-Reference-Cited by-同舟云学术

Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region

Published:2018-10-18 Issue:1 Volume:22 Page:9-24
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Rath Prasan Deep¹,Chen Der-Yuan²³,Gu Jieruo⁴,Lee Vivian W. Y.⁵,Al Ani Nizar Abdulateef⁶,Shirazy Khalid⁷,Llamado Lyndon⁸

Affiliation:

1. Max Super Speciality Hospital; Delhi India

2. Department of Medicine; Center of Rheumatology and Immunology; China Medical University Hospital; Taichung Taiwan

3. School of Medicine; China Medical University; Taichung Taiwan

4. Department of Rheumatology; Third Affiliated Hospital of Sun Yat-sen University; Guangzhou China

5. School of Pharmacy; The Chinese University of Hong Kong; Shatin, N.T. Hong Kong

6. Rheumatology Unit; Department of Medicine; College of Medicine; University of Baghdad; Baghdad Iraq

7. Pfizer; Media City Dubai UAE

8. Pfizer; Makati City Philippines

Funder

Pfizer

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.13371/fullpdf

Reference120 articles.

1. Core management principles in rheumatoid arthritis to help guide managed care professionals;Agarwal;J Manag Care Pharm,2011

2. The changing landscape of biosimilars in rheumatology;Dörner;Ann Rheum Dis,2016

3. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study;An;Clin Rheumatol,2017

4. Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study;Xu;Arthritis Care Res (Hoboken),2014

5. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand;Osiri;J Rheumatol,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physicians’ and patients’ perception of biosimilars and factors affecting biosimilar prescribing in selected Asian Countries: a survey study;Expert Opinion on Biological Therapy;2024-09-05

2. Glyceroglycolipids in marine algae: A review of their pharmacological activity;Frontiers in Pharmacology;2022-10-21

3. Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review;The Lancet Regional Health - Europe;2021-10

4. The perennial search for alternatives to corticosteroids in rheumatology: is there light at the end of the tunnel?;Clinical Rheumatology;2020-08-22

5. A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects;Clinical Pharmacology in Drug Development;2020-05-28